Why the study?
To precisely mimic the human TNNT1 nonsense mutation causing Amish Nemaline Myopathy and evaluate its pathogenic mechanisms compared with loss-of-function ssTnT knockout.
Does the Tnnt1 p.Glu180* knock-in mutation cause more severe myopathy than ssTnT knockout in a mouse model of Amish Nemaline Myopathy?
Does the Tnnt1 p.Glu180* knock-in mutation cause more severe myopathy than ssTnT knockout in a mouse model of Amish Nemaline Myopathy?
The study demonstrates that a knock-in mouse model of Amish Nemaline Myopathy exhibits more severe myopathy than a knockout model, suggesting that truncated ssTnT fragments have potent cytotoxicity contributing to disease pathogenesis.
Highlights potential ssTnT fragment cytotoxicity in Amish Nemaline Myopathy models; leaves open human translation and therapeutic targeting.
A nonsense mutation in codon Glu 180 of the TNNT1 gene, which encodes the slow skeletal muscle isoform of troponin T (ssTnT), causes a recessively inherited myopathy (the Amish Nemaline Myopathy, ANM). A ssTnT knockout (ssTnT‐KO) mouse model produced the loss of ssTnT function phenotypes of ANM with slow fiber atrophy and decreased fatigue resistance of soleus muscle. We further developed a Tnnt1 p.Glu180* knock‐in (ANM‐KI) mouse model to precisely mimic the human mutation. In addition to reproducing the loss of function phenotypes, ANM‐KI mice exhibit more severe myopathy than that of ssTnT‐KO mice. Compared with wild‐type controls, ANM‐KI and ssTnT‐KO soleus muscles show different changes in gene expression profiles, of which gene ontology analysis indicated inflammatory activation in ANM‐KI soleus muscle. The mutant Tnnt1 mRNA was readily detectable in ANM‐KI soleus muscle. However, the truncated ssTnT 1–179 fragment cannot be detected in western blot, indicating its very low level due to the active proteolytic clearance of non‐myofilament‐incorporated TnT in muscle cells. Nonetheless, the more severe myopathic impacts of the ANM‐KI allele with more fiber number loss and muscle activity/injury‐caused hypertrophy support a potent cytotoxicity of the ssTnT fragment, as shown in previous cell culture studies, which is further supported by activity‐dependent and age‐progressing myopathy with more active regeneration. The notion that non‐myofilament‐incorporated ssTnT fragments may potentially contribute to the pathogenesis and progression of myopathy merits further investigation.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: